Search

Your search keyword '"Miranda, Roberto N."' showing total 191 results

Search Constraints

Start Over You searched for: Author "Miranda, Roberto N." Remove constraint Author: "Miranda, Roberto N." Journal blood Remove constraint Journal: blood
191 results on '"Miranda, Roberto N."'

Search Results

4. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL

5. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis

6. Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.

7. Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin

9. Cutaneous/ Subcutaneous Involvement - an Immuneprivileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.

10. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

11. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

13. Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma

14. CD70 Expression in Mature T-Cell Lymphomas

15. Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series

16. Radiomic Phenotypes of High and Low Lesion SUV Components for the Prediction of Refractory Disease in Hodgkin's Lymphoma Patients Treated with ABVD Based Therapy

17. Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series

18. Real Life Treatment Alterations of Frontline Therapies in Classic Hodgkin's Lymphoma

19. Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma

20. A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)

21. Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center

22. Association of Smoking with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma

23. Association of Epstein-Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma

24. Association of Vitamin D Deficiency with Inferior Treatment Outcomes in Patients with Newly Diagnosed Classic Hodgkin Lymphoma: MD Anderson Cancer Center Experience

25. A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

26. Maintenance Rituximab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in the First Line Setting or at Relapse

28. MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients

32. The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma

33. MYC Copy Number Aberrancies Predict a Worse Prognosis in Patients with Diffuse Large B-Cell Lymphoma

35. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL

36. ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response

37. MYC/BCL2 Double Hit Lymphoma: What Really Matters

38. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma

39. Integrated Genome Sequencing Reveals Frequent Loss of Function Alterations of ARID1A and Other Epigenetic Modifiers in Sezary Syndrome

40. ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition

41. Novel Gene Translocations Involving TYK2 in Cutaneous CD30-Positive Lymphoproliferative Disorders

42. Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program

43. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

45. HIV-Associated Plasmablastic Lymphoma: A Multi-Institutional Study

46. The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study

48. A novel recurrent NPM1-TYK2gene fusion in cutaneous CD30-positive lymphoproliferative disorders

49. Evidence That Some Breast Implant Associated Anaplastic Large Cell Lymphomas Arise in the Context of Allergic Inflammation

50. MYCCopy Number Aberrancies Predict a Worse Prognosis in Patients with Diffuse Large B-Cell Lymphoma

Catalog

Books, media, physical & digital resources